



Review

The neurobiological basis for novel experimental therapeutics in dystonia

Anthony M. Downs^{a,1}, Kaitlyn M. Roman^{a,1}, Simone A. Campbell^a, Antonio Pisani^{b,c},
Ellen J. Hess^{a,d}, Paola Bonsi^{b,*}

^a Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA 30322, USA

^b Laboratory of Neurophysiology and Plasticity, IRCCS Fondazione Santa Lucia, 00143 Rome, Italy

^c Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy

^d Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, USA

ARTICLE INFO

Keywords:

Basal ganglia
Cerebellum
Drug discovery
Anatomy
Therapy
Animal models

ABSTRACT

Dystonia is a movement disorder characterized by involuntary muscle contractions, twisting movements, and abnormal postures that may affect one or multiple body regions. Dystonia is the third most common movement disorder after Parkinson's disease and essential tremor. Despite its relative frequency, small molecule therapeutics for dystonia are limited. Development of new therapeutics is further hampered by the heterogeneity of both clinical symptoms and etiologies in dystonia. Recent advances in both animal and cell-based models have helped clarify divergent etiologies in dystonia and have facilitated the identification of new therapeutic targets. Advances in medicinal chemistry have also made available novel compounds for testing in biochemical, physiological, and behavioral models of dystonia. Here, we briefly review motor circuit anatomy and the anatomical and functional abnormalities in dystonia. We then discuss recently identified therapeutic targets in dystonia based on recent preclinical animal studies and clinical trials investigating novel therapeutics.

1. Introduction

Dystonia, the third most common movement disorder after tremor and Parkinson's disease (Defazio, 2010), is characterized by involuntary muscle contractions that cause twisting movements and postures (Albanese et al., 2013). The causes of dystonia are diverse. It may occur as a sporadic (idiopathic) or inherited disorder (Schwarz and Bressman, 2009; Tanabe et al., 2009) and can sometimes occur as a result of brain injury (Frei et al., 2004; Krauss and Jankovic, 2002; Lo et al., 2005). The clinical features of dystonia are also heterogeneous. In some patients, dystonia affects only a small number of muscles, such as those of the hand in writer's cramp or those of the neck in torticollis. In others, muscles throughout the body are involved. Although dystonia is not lethal, it is debilitating. Indeed, standardized quality of life scores for dystonia fall into the same range as Parkinson's disease, stroke and multiple sclerosis (Camfield et al., 2002). Despite the prevalence and detrimental impact on quality of life, patients have very limited treatment options and struggle to find off-label alternatives that are rarely efficacious. Therefore, this review examines promising drug targets for dystonia, and presents a summary of recent preclinical, animal studies and clinical trials supporting their efficacy.

2. Motor circuit anatomy

The scarcity of small molecule drugs for the treatment of dystonia is directly attributable to the lack of clearly validated therapeutic targets; dystonia is not typically associated with degeneration or evident neuropathological abnormalities and the underlying cellular mechanisms are largely unknown. However, convergent evidence from clinical investigation and experimental models supports the view that dystonia is a circuit disorder, involving both the basal ganglia-thalamo-cortical and cerebello-thalamo-cortical pathways. Thus, a better understanding of how these networks function both normally and in dystonia is critical for discovering new therapeutics.

2.1. The cortico-basal ganglia-thalamo-cortical pathway

The basal ganglia are subcortical nuclei involved in diverse functions, including motor control and motor learning, executive function, and emotion. The basal ganglia include the striatum (caudate-putamen and nucleus accumbens), globus pallidus, subthalamic nucleus (STN), substantia nigra, and pedunculopontine nucleus (PPN). In brief, information flows through the basal ganglia back to the cortex through

* Corresponding author.

E-mail address: p.bonsi@hsantalucia.it (P. Bonsi).

¹ Co-first authors.




Fig. 1. Simplified cartoon of basal ganglia-cerebellum anatomical connections. **A.** The cartoon depicts a simplified cortico-basal ganglia-thalamo-cortical circuit. Afferents from the cortex and thalamus (left, brown arrows) reach caudate and putamen neuronal populations of cholinergic interneurons (right, green) and projection neurons. Spiny projection neurons give rise to the direct (right, dark brown) and indirect (right, blue) output pathways, ultimately reaching the basal ganglia output nuclei (globus pallidus externus and substantia nigra pars reticulata), which send the processed information to the thalamus (left, red arrows). The thalamus then projects back to the cortex (left, red arrow). **B.** The cartoon depicts simplified cortico-cerebello-thalamo-cortical connections. Left. The cerebellar cortex has a trilaminar cytoarchitecture composed of the Purkinje cell layer and the molecular layer (green), and of the granular layer (granule cells, red). Parallel fibers (red), originating from granule cells, reach the molecular layer and innervate inhibitory stellate (blue) and basket interneurons, as well as Purkinje cells (green). Purkinje cells are also activated by climbing fibers (blue), which originate in the inferior olive. The pontine nucleus receives cortical afferents and is a source of mossy fibers reaching the contralateral cerebellar cortex (light green arrow). Purkinje cells project to the deep cerebellar nuclei, which in turn convey cerebellar output to the cortex via the thalamus (green arrows). **C.** Retrograde transneuronal transport of rabies virus in monkeys revealed bidirectional disynaptic connections between the cerebellum and the basal ganglia. Specifically, a pathway originating from the deep cerebellar nuclei and reaching the putamen (blue arrows; Hoshi et al., 2005), and a pathway connecting the subthalamic nucleus to the cerebellar cortex (dark blue arrows; Bostan et al., 2010) were identified. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

two pathways with opposing effects on movement execution: the “direct pathway” and the “indirect pathway” (Albin et al., 1989; DeLong, 1990). The original model of basal ganglia organization was based on experimental and clinical evidence of opposite functional effects of the direct and indirect projections on the output structures, which facilitate or inhibit movements, respectively (Gerfen, 2000). This model, which is supported by evidence from genetic, lesion and optogenetic studies,

proposes that during normal behavior the direct pathway promotes a specific motor program while the indirect pathway inhibits competing motor programs (Bateup et al., 2010; Durieux et al., 2009; Kravitz et al., 2010). However, this model has undergone significant revisions to reflect more recent evidence demonstrating that direct and indirect pathways are not as segregated as originally proposed (Cui et al., 2013; Tecuapetla et al., 2016).

The striatum is the input nucleus of the basal ganglia. The striatum receives dopaminergic (DA) afferents from neurons originating in the substantia nigra pars compacta (SNc) and ventral tegmental area. The striatum also receives glutamatergic input from the cerebral cortex and thalamus. Dopaminergic and glutamatergic input to the striatum is integrated by GABAergic spiny projection neurons (SPNs), the major output neurons of the striatum. SPNs compose $\geq 95\%$ of neurons in the striatum (Kawaguchi, 1993; Tepper et al., 2010). SPNs of the indirect striatopallidal pathway innervate the external segment of the globus pallidus (GPe) and express the dopamine (DA) D2 receptor. SPNs of the direct striatonigral pathway express the D1 DA receptor, and project directly to the internal segment of the globus pallidus (GPI) and the substantia nigra pars reticulata (SNr). The GABAergic GPI and SNr neurons send inhibitory input to the ventral and intralaminar thalamic nuclei. Thalamic glutamatergic neurons then provide excitatory input to the motor cortex, which projects to spinal motor neurons or provides feedback to the striatum. In the indirect pathway, striatopallidal neurons provide inhibitory GABAergic input to GABAergic GPe neurons, which in turn provide inhibitory input to the STN. Glutamatergic neurons in the STN provide excitatory input to the GPI and SNr, which inhibit the thalamus and cortex (Albin et al., 1989; Parent and Hazrati, 1995). The remaining $\sim 5\%$ of striatal neurons are represented by several different classes of interneurons, including: cholinergic interneurons (ChIs), GABAergic fast-spiking interneurons (FSIs), and other peptidergic interneurons (Kawaguchi, 1997). Some striatal interneurons, such as ChIs and FSIs, respond to dopaminergic signaling and reciprocally modulate both SPNs and other interneuron populations (Gittis et al., 2010; Gritton et al., 2019; Tepper et al., 2008).

2.2. The basal ganglia connections with the cerebello-thalamo-cortical pathway

The cerebellum forms complex, large-scale connections with other brain regions and has a well-characterized role in motor learning and control. The cerebellar cortex has a trilaminar cytoarchitecture composed of the granular layer, the molecular layer, and the Purkinje cell layer. In the granular layer, mossy fiber afferents from extracerebellar regions activate granule cells and Golgi cells. Granule cells form ascending axons, called parallel fibers, which extend within the molecular layer. In the molecular layer, parallel fibers innervate inhibitory stellate and basket interneurons as well as Purkinje cells. Purkinje cells are also activated by climbing fibers, which originate in the inferior olive. The Purkinje cells project to the deep cerebellar nuclei, which in turn convey cerebellar output to other brain regions.

Anatomical and functional data support several bidirectional cerebello-thalamo-cortical circuits connecting the cerebellar cortex to motor, sensory, or associative cerebral cortical areas (Gornati et al., 2018; Krienen and Buckner, 2009; Schmahmann et al., 2019). Recent work uncovered an anatomical substrate between the basal ganglia and cerebellum, suggesting these structures may form an integrated functional network. Bidirectional communication occurs through a disynaptic projection from the dentate nucleus of the cerebellum to the striatum (Hoshi et al., 2005) and a disynaptic projection from the subthalamic nucleus of the basal ganglia to the cerebellar cortex (Bostan et al., 2010). This network is topographically organized, whereby the motor, cognitive and affective territories of the basal ganglia, cerebellum and cerebral cortex are interconnected. It is now accepted that the basal ganglia, cerebellum, and cerebral cortex form an integrated network, and this basal ganglia-to-cerebellar pathway plays a role in dystonic movements (Fig. 1) (Bostan et al., 2018; Neychev et al., 2008; Shakkottai et al., 2017).

3. Anatomical basis of dystonia

Historically, dystonia has been viewed as a disease of the basal ganglia due to the wealth of evidence implicating this region. In

patients with hemidystonia, focal brain lesions were identified in the basal ganglia or associated regions (Bhatia and Marsden, 1994). Further, comorbidity of dystonia with other diseases of the basal ganglia, such as Parkinson's disease (Tolosa and Compta, 2006) and Huntington's disease (Louis et al., 1999), suggested involvement of the basal ganglia in the pathology of dystonia.

Human imaging studies have also implicated the basal ganglia in dystonia. In summary, functional magnetic resonance imaging studies of dystonia patients that reveal changes in basal ganglia activity generally show an increase in activation, particularly in the caudate, putamen and globus pallidus (Blood et al., 2004; Haslinger et al., 2010; Schneider et al., 2010). Voxel-based morphometry studies reveal alterations in volume of basal ganglia nuclei. In these studies, regional volume was increased in the caudate and decreased in the putamen of patients with cervical dystonia and blepharospasm (Obermann et al., 2007), though others have observed opposing trends within these regions (Draganski et al., 2009). Within the globus pallidus, regional volume is generally increased (Draganski et al., 2009; Draganski et al., 2003; Egger et al., 2007). Positron emission tomography (PET) imaging studies demonstrate a reduction in striatal D2 DA receptor availability in patients with DYT1 dystonia, writer's cramp and spasmodic dysphonia (Asanuma et al., 2005b; Berman et al., 2013; Simonyan et al., 2013), and an increase in the availability of striatal D1 DA receptors in individuals with laryngeal dystonia and focal hand dystonia (Simonyan et al., 2017), which may contribute to an imbalance in the direct and indirect basal ganglia pathways. [^{18}F]-fluorodeoxyglucose-PET imaging demonstrate that glucose metabolism is increased within the caudate and putamen in patients with cervical dystonia and DYT1 dystonia (Carbon et al., 2004; Galardi et al., 1996), though others have noted a reduction in activity in the putamen in dopa-responsive dystonia (DRD) patients (Asanuma et al., 2005b). These findings have been reviewed extensively (Asanuma et al., 2005a; Jinnah et al., 2017; Lehericy et al., 2013; Neychev et al., 2011; Simonyan, 2018) and point to the many associations between basal ganglia dysfunction and dystonia. Targeted interventions to basal ganglia nuclei for the treatment of dystonia such as pallidotomy (Lozano et al., 1997) and deep-brain stimulation of the GPI and STN (Ostrem et al., 2017; Ostrem and Starr, 2008) are also compelling evidence.

Although abundant evidence supports the role of the basal ganglia in dystonia, other regions, including the cerebellum, are also involved (Bologna and Berardelli, 2018; Neychev et al., 2011; Shakkottai et al., 2017). For example, cerebellar lesions occur in patients with cervical dystonia (LeDoux and Brady, 2003). Further, post-mortem analysis of brains from patients with cervical dystonia revealed loss of Purkinje cells, increased gliosis, and inclusions of torpedo bodies within Purkinje cells (Prudente et al., 2013). Additionally, there is an increase in metabolic activity in the cerebellum in myoclonus dystonia and cervical dystonia as assessed by PET imaging (Carbon et al., 2013; Eidelberg et al., 1998), and fMRI studies show alterations in cerebellar activation in individuals with dystonia (Filip et al., 2017; Prudente et al., 2016). Moreover, evidence from animal models also implicates the cerebellum in dystonia. Dystonia in both tottering mice (Campbell et al., 1999) and the Dt rat (LeDoux, 2011) arises from cerebellar dysfunction. Additionally, cerebellar knockdown of *Tor1a*, the gene associated with DYT1 dystonia, results in dystonic movements in wild-type mice, while striatal knockdown does not induce dystonia (Fremont et al., 2017). Dystonia can also be induced in normal mice by pharmacological manipulation of cerebellar signaling using glutamatergic agonists (Fan et al., 2018; Pizoli et al., 2002) or the sodium-potassium pump blocker ouabain (Calderon et al., 2011).

Although the basal ganglia and the cerebellum have been the primary focus of dystonia research, other regions are implicated in dystonia. For example, brainstem lesions are sometimes associated with dystonia, and thalamic stimulation or ablation has been used to treat hand dystonia (Shimizu et al., 2018). Involvement of these other regions has been reviewed elsewhere (Jinnah et al., 2017; Neychev et al.,

2011; Schirinzi et al., 2018) and has led to the development of the motor network model of dystonia. Understanding these anatomical substrates and their interactions provides a platform for the development of improved therapies for the treatment of dystonia.

4. Existing treatments for dystonia

Current treatments for dystonia include oral pharmaceuticals, botulinum toxin, and surgical procedures (Cloud and Jinnah, 2010; Thenganatt and Jankovic, 2014). Here, the focus is on oral pharmaceuticals. Trihexyphenidyl (THP), a nonselective muscarinic acetylcholine receptor (mAChR) antagonist is the only widely used oral pharmaceutical that has been studied in a double-blind controlled trial for dystonia. This clinical trial demonstrated that THP was effective at alleviating dystonia in approximately 70% of patients (Burke et al., 1986). While THP is an effective treatment, it is often poorly tolerated due to significant side effects, including: cognitive impairments, memory loss, nightmares, dry mouth, constipation, blurred vision, and urinary retention (Bymaster et al., 2003; Jabbari et al., 1989; Lumsden et al., 2016). These side effects are often exacerbated by the high doses of THP needed to treat dystonia (Lang, 1986). Other nonselective mAChR antagonists have been used clinically, including atropine (Lang et al., 1982), procyclidine (Paulson, 1960), biperiden (Lang et al., 1982; Stern and Anderson, 1979), and biperiden (Cloud and Jinnah, 2010).

Despite the clear involvement of dopaminergic transmission in the pathophysiology of dystonia (Karimi and Perlmutter, 2015; Thompson et al., 2011), DA agonists, including direct D1/D2 receptor agonists and indirect agonists such as L-DOPA and amphetamine, are generally not effective treatments for dystonia. The exception is the use of L-DOPA to treat patients with DRD, a form of dystonia caused by mutations in genes involved in catecholamine synthesis. However, there are some reports that suggest DA receptor agonists may be effective in subsets of dystonia patients in addition to those with DRD (Fan et al., 2018).

Other pharmaceuticals have been used to treat dystonia, with varying degrees of success. Baclofen, a presynaptic GABA_B receptor antagonist, is sometimes used in dystonia. However, a meta-analysis of clinical trials and case reports found that baclofen improved symptoms in only 20% of patients with dystonia (Greene et al., 1988). Other pharmaceuticals used to treat dystonia are: benzodiazepines, muscle relaxants, and anti-epilepsy medications, although there is limited evidence for the efficacy of any of these for the treatment of dystonia (Thenganatt and Jankovic, 2014).

5. New experimental therapeutic and pharmacological targets

In light of the limited and sometimes ineffective treatments for dystonia, there is significant interest in developing new therapeutics for the treatment of dystonia. There are several broad approaches to identifying new therapeutics: refining existing therapeutics to improve efficacy and limit off-target effects, identifying pharmacological targets that are implicated in multiple forms of dystonia, or investigating pharmacological targets that are implicated in other movement disorders, such as L-DOPA induced dyskinesias (LIDs). Below, we review recent preclinical and clinical work to identify new therapeutics and therapeutic targets. To date, most preclinical studies have focused on therapeutic targets in the basal ganglia. Although the cerebellum is clearly implicated (Tewari et al., 2017), less is known about targets in this region. For a summary of recent preclinical and clinical studies see Table 1.

5.1. Antimuscarinic receptor antagonists

While nonselective mAChR antagonists are effective in many forms of dystonia, they are often poorly tolerated due to debilitating side effects. Several studies have attempted to improve the therapeutic

potential of mAChR antagonists by identifying the specific mAChR subtype(s) that mediate the therapeutic effects of THP and other non-selective mAChR antagonists. These studies have been facilitated by the recent development of truly selective mAChR antagonists and modulators (Bender et al., 2018; Lewis et al., 2008; Marlo et al., 2009; Wood et al., 2017).

In general, mAChR antagonists are thought to improve dystonia by modulating ACh in the striatum. ChIs and cholinergic afferents from the PPN and laterodorsal tegmental nuclei provide ACh to the striatum, although most research has focused on ChIs (Brimblecombe et al., 2018; Dautan et al., 2016). ChIs constitute less than 1% of all neurons in the striatum, but they have broad axonal arborizations that cover most of the striatum (Gonzales and Smith, 2015). ChIs are tonically active and are modulated by dopaminergic and glutamatergic afferents as well as GABAergic neurons in the striatum (Cai and Ford, 2018; Dawson et al., 1990; Kosillo et al., 2016; Tepper et al., 2008; for review see: Bonsi et al., 2011). ACh modulates striatal activity via both nicotinic acetylcholine receptors (nAChR) and mAChR. In the striatum, nAChR are expressed on presynaptic terminals of nigral dopaminergic afferents and glutamatergic cortical and thalamic afferents (Exley et al., 2008). mAChRs are divided into two broad classes: M₁, M₃, and M₅ subtypes coupled to Gα_q, and M₂ and M₄ subtypes coupled to Gα_{i/o}. Corticostriatal terminals express M₂, M₃, and M₄ mAChR that modulate glutamate release (Girasole and Nelson, 2015; Pancani et al., 2014). Direct SPNs express M₁ and M₄ mAChR, while indirect SPNs express only M₁ mAChR (Alcantara et al., 2001; Harrison et al., 1996; Hernandez-Flores et al., 2015). Both mAChR subtypes on SPNs modulate corticostriatal plasticity. In contrast, M₅ mAChR are restricted to DA neurons and modulate DA release (Foster et al., 2014). ChIs express M₂ and M₄ mAChR autoreceptors that reduce tonic firing and inhibit ACh release (Bonsi et al., 2008; Dawson et al., 1990; Girasole and Nelson, 2015; Threlfell et al., 2010).

To date, two mechanisms have been proposed to mediate the therapeutic effects of THP in dystonia, although these mechanisms are not mutually exclusive. A recent study found THP normalizes DA release in a mouse knockin model of DYT1 dystonia. This effect is likely mediated by M₂ and/or M₄ mAChRs on ChIs and depends on nAChR to indirectly mediate the effect of THP on DA release (Downs et al., 2019). However, it is worth noting that this study did not specifically rule out other mAChR subtypes that may mediate the increase in DA release after THP administration. Indeed, previous studies have shown that M₁, M₄, and M₅ mAChRs modulate DA release in striatal sections (Zhang et al., 2002). THP may also produce therapeutic effects by normalizing corticostriatal plasticity in dystonia. Previous studies have identified abnormal corticostriatal long-term depression (LTD) as a common pathology in Dyt1 mouse models (Maltese et al., 2018; Martella et al., 2009, 2014). Abnormal LTD is thought to be mediated by ChI dysfunction, which has been consistently identified in Dyt1 knockin mice (Scarduzio et al., 2017; Sciamanna et al., 2012). THP restores normal patterns of corticostriatal LTD (Dang et al., 2012; Martella et al., 2014) and this effect is mimicked by the M₁ mAChR selective antagonist VU0255035 (Maltese et al., 2014). Alternatively, M₁ mAChR antagonists may simply block the excitatory effects of M₁ mAChR on striatal spiny projection neurons to ameliorate dystonia.

However, THP may improve dystonia by other mechanisms, which may involve other mAChR subtypes and other brain regions. A study in a mouse model of DRD found that THP improves dystonic movements, although it is unclear if its therapeutic effects are restricted to the striatum or involve other brain regions (Rose et al., 2015). mAChRs are expressed throughout the basal ganglia and other areas of the brain (Weiner et al., 1990), and, accordingly, the therapeutic actions of THP may not be restricted to the striatum. One study in the dt^{sz} hamster demonstrated that M₁- and M₄-preferring mAChR antagonists improved dystonia, although the mechanism of action was less clear given the limited mAChR subtype selectivity of the compounds used (Hamann et al., 2017). Therapeutics targeting specific mAChR subtypes may

Table 1
Summary of recent preclinical and clinical work to identify new therapeutics and therapeutic targets for dystonia.

Target	Type of study	Model/patient population	Compound	Outcome	Reference
Antimuscarinics	Clinical trial (randomized, double-blind, placebo)	31 adults (dystonia)	Trihexyphenidyl	Improved dystonia	(Burke et al., 1986)
	Clinical trial (open label)	23 children (dystonia) 52 adults (dystonia)	Trihexyphenidyl ethopropazine	Improved dystonia	(Fahn, 1983)
Nicotinic receptors	Animal study	Dyt1 knockin mice	Trihexyphenidyl	Normalized DA release	(Downs et al., 2019)
	Animal study	Dyt1 knockin mice dt ^{sz} hamster	Trihexyphenidyl VU0255035 (M ₁ antagonist) Trihexyphenidyl tropicamide	Normalized corticostriatal plasticity Improved dystonia	(Maltese et al., 2014) (Hamann et al., 2017)
mGluR5 receptors A2A adenosine receptors	Case reports	2 adults (hemidystonia)	Nicotine (lozenges and transdermal patch)	Improved dystonia	(Lees, 1984) (Vaughan et al., 1997)
	Animal study	Dyt1 knockin mice	AZD1446 (non-desensitizing nAChR agonist)	No effect on DA release/ overflow	(Zimmerman et al., 2017)
	Animal study	Dyt1 knockin mice	ADX48621 (mGluR5 NAM)	Normalized corticostriatal plasticity	(Sciamanna et al., 2014)
	Animal study	Dyt1 knockin mice	KW6002 (A2A receptor antagonist)	Normalized corticostriatal plasticity	(Napolitano et al., 2010)
	Animal study	Dyt11 knockin mice	SCH 58261 (A2A receptor antagonist)	Normalized corticostriatal plasticity	(Maltese et al., 2017)
	Animal study	dt ^{sz} hamster	CPA (N(6)-cyclopentyladenosine (A1A receptor agonist)	Improved dystonia	(Richter and Hamann, 2001)
	Animal study	dt ^{sz} hamster	CGS 21680 (A2A receptor agonist)	Worsened dystonia	(Richter and Hamann, 2001)
	Animal study	dt ^{sz} hamster	Non-selective adenosine receptor antagonists A1A receptor antagonists	Worsened dystonia	(Richter and Loscher, 1994)
	Animal study	dt ^{sz} hamster	WIN 55,212-2 (CB ₁ agonist)	Improved dystonia	(Richter and Loscher, 2002)
	Animal study	dt ^{sz} hamster	WIN 55,212-2 (CB ₁ agonist)	Improved dystonia	(Fox et al., 2002)
Endocannabinoid receptors (CB ₁)	Clinical trial (randomized, double-blind, placebo controlled)	15 (primary dystonia)	Nabilone (CB ₁ /CB ₂ agonist)	No improvement	(Zadikoff et al., 2011)
	Clinical trial (randomized, placebo controlled)	9 (cervical dystonia)	Dronabinol (CB ₁ /CB ₂ agonist)	No improvement	(Zadikoff et al., 2011)
NMDA receptors	Clinical trial (open-label)	5 (undefined dystonia)	Cannabidiol (CB ₁ /CB ₂ partial agonist)	Improved dystonia	(Conroe et al., 1986)
	Animal study	dt ^{sz} hamster	NVP-AAM077 (NR2A antagonist)	Improved dystonia	(Avshalumov et al., 2014)
SV2A modulators	Animal study	dt ^{sz} hamster	Ro 25-6981 (NR2B antagonist)	Worsened dystonia	(Richter, 2003)
	Animal study	dt ^{sz} hamster	Piracetam	Improved dystonia	(Loscher and Richter, 2000)
	Animal study	dt ^{sz} hamster	Levetiracetam	Improved dystonia	(Hamann et al., 2008)
	Animal study	dt ^{sz} hamster	Brivaracetam Seletiracetam	Improved dystonia	(Park et al., 2017)
EIF2 α signaling	Clinical trial	7 (cranial and oromandibular dystonia)	Levetiracetam	No improvement	(Hering et al., 2007)
	Clinical trial	10 (generalized/ segmental dystonia)	Levetiracetam	No improvement	(Hering et al., 2007)
BDNF signaling	Case report	1 (generalized dystonia)	Levetiracetam	Significant improvement	(Sullivan et al., 2005)
	Case report	1 (Meige's syndrome)	Levetiracetam	Significant improvement	(Yardinci et al., 2006)
BDNF signaling	Animal study	Dyt1 knockin mice	Salubrital (eIF2 α dephosphorylation inhibitor)	Rescued ER function and abnormal torsinA localization	(Rittiner et al., 2016)
	Animal study	Dyt1 knockin mice	ANA-12 (TrkB inhibitor)	Normalized corticostriatal plasticity	(Maltese et al., 2018)

enhance the treatment of dystonia by minimizing off-target side effects. However, additional studies are needed to further characterize the role of each mAChR subtype in dystonia.

5.2. Nicotinic receptor agonists

Nicotinic receptor (nAChR) agonists have been proposed as novel therapeutics for dystonia based on evidence implicating abnormal striatal ACh signaling in animal models of dystonia (Eskow Jaunarajs et al., 2015), and from two case reports that show nicotine lozenges and patches are effective in treating dystonia (Lees, 1984; Vaughan et al., 1997). Nicotine is thought to improve dystonia by activating nAChRs on DA terminals in the striatum or DA cell bodies in the SNc, which increases the firing rate of DA neurons, increases striatal DA release, and changes the amplitude of DA release in response to tonic and phasic firing of DA neurons (Grenhoff et al., 1986; Rice and Cragg, 2004; Threlfell and Cragg, 2011). However, a recent study in a knockin mouse model of DYT1 dystonia showed the non-desensitizing agonist, AZD1446, did not normalize or increase extracellular DA in this model (Zimmerman et al., 2017). In contrast to nAChR agonists, nAChR positive allosteric modulators may warrant further investigation because they might subtly increase DA release without desensitizing nAChRs.

5.3. Dopamine receptor agonists

DA modulates the activity of most striatal neurons including SPNs, the sole output neurons of the striatum. The two main classes of DA receptors are defined based on their ability to modulate adenylyl cyclase: D1-class DA receptors (D1, D5) which couple to $G\alpha_{olf}$ or $G\alpha_s$, and D2-class DA receptors (D2, D3, D4) which couple to $G\alpha_{i/o}$ (Andersen et al., 1990; Keabian and Calne, 1979; Niznik and Van Tol, 1992; Sibley and Monsma Jr., 1992; Tiberi et al., 1991). Within the striatum, D1 receptors are almost exclusively expressed on direct SPNs (Corvol et al., 2001; Zhuang et al., 2000). In contrast, D2 receptors are expressed on indirect SPNs and ChIs, where they reduce neuronal firing, and on presynaptic DA terminals, where they inhibit DA release and regulate DA synthesis (Dawson et al., 1990; De Mei et al., 2009; Giros et al., 1989; Monsma Jr. et al., 1989; Usiello et al., 2000). D3, D4, and D5 receptors are also found in the basal ganglia at lower levels (Gainetdinov et al., 1996; Huntley et al., 1992; Missale et al., 1998; Rivera et al., 2002; Rondou et al., 2010).

Clinical research suggests a common cellular mechanism underlying various forms of dystonia is disrupted DA neurotransmission (Nemeth, 2002; Perlmutter and Mink, 2004; Wichmann, 2008). Reduced DA neurotransmission is associated with dystonia in inherited disorders such as DOPA-responsive dystonia (Furukawa et al., 1996; Ichinose et al., 1995, 2000), DA transporter deficiency syndrome (Kurian et al., 2011), amino acid decarboxylase deficiency (Brun et al., 2010), VMAT2 deficiency (Rilstone et al., 2013), and Lesch-Nyhan disease (Lloyd et al., 1981). Reduced DA neurotransmission is also observed in more common idiopathic dystonias such as writer's cramp (Berman et al., 2013) and spasmodic dysphonia (Simonyan et al., 2013). Further, dystonia can occur in response to therapy with DA receptor antagonists (i.e. tardive dystonia) (Mahmoudi et al., 2014) and is often co-morbid with degenerative disorders that affect DA neurons such as Parkinson's disease (Lopez-Ariztegui et al., 2009). These observations suggest that restoring striatal DA with direct or indirect DA agonists should improve dystonia (Karimi and Perlmutter, 2015).

Paradoxically, DA agonists are seldom used to treat dystonia, with the exception of DRD. However, a recent meta-analysis suggests there is insufficient evidence in the literature to make definitive conclusions about the efficacy of DA agonists in dystonia (Fan et al., 2018). In fact, previous case reports and small clinical studies demonstrate that amphetamine (Myerson and Loman, 1942), apomorphine (Micheli et al., 1982), bromocriptine (Stahl and Berger, 1981), and lisuride (Micheli and Fernandez Pardal, 1986) are effective in some patients with

idiopathic dystonia. Apomorphine is a partial agonist at both D1 and D2 class receptors, whereas bromocriptine and lisuride are D2-like receptor agonists. D2-like receptors agonists are more commonly used to treat dystonia, whereas D1-like receptor-selective agonists are not yet available for use in humans, although they are effective in animal models of dystonia (Fan et al., 2018; Rose et al., 2015). It is thought that D2 and D1/D2 agonists improve dystonia by mimicking normal DA receptor activation of SPNs, which normalizes the activity of the direct and indirect pathways in the basal ganglia (Rose et al., 2015).

Recent studies in animal models of dystonia, especially Dyt1 mice, have suggested that D2 receptors on ChI may be a target for therapeutics. ChIs exhibit abnormal responses to D2 receptor activation in several Dyt1 mouse models. While D2 receptor activation normally reduces the firing rate of ChIs, D2 receptor activation increases ChI firing rate in Dyt1 mice (Napolitano et al., 2010; Sciamanna et al., 2012, 2014). This abnormal D2 receptor signaling is mediated by a switch from $G\alpha_{i/o}$ protein signaling to β -arrestin signaling (Bonsi et al., 2019; Scarduzio et al., 2017). Furthermore, a recent study found that overexpressing the striatal-specific RGS9-2 regulatory protein functionally inhibits β -arrestin and restores normal D2 receptor function in ChIs of Dyt1 mice (Bonsi et al., 2019). Taken together, these studies suggest that D2 receptor agonists biased towards G-protein mediated signaling may be effective therapeutics in DYT1 dystonia. These studies also identify RGS9-2, a target previously proposed for other disorders (Sjögren, 2017; Traynor et al., 2009), as a novel therapeutic target for dystonia. Future studies should evaluate the therapeutic efficacy of RGS9-2 potentiators in dystonia.

5.4. mGluR5 negative allosteric modulators (NAMS)

The effects of glutamate are mediated by two families of receptors, metabotropic and ionotropic, which are categorized by their mode of signal transduction. Metabotropic glutamate receptors are subdivided into three groups: Group I (mGluRs 1 and 5), Group II (mGluRs 2 and 3), and Group III (mGluRs 4, 6, 7, and 8) (Conn and Pin, 1997). In general, Group I mGluRs are located postsynaptically and couple to $G\alpha_{q/11}$, whereas Groups II and III are localized presynaptically and couple to $G\alpha_{i/o}$ (Niswender and Conn, 2010). Group I mGluRs have been most extensively evaluated for therapeutic efficacy in dystonia. Within the striatum, mGluR5 receptors are expressed on SPNs as well as FSIs, ChIs, and low-threshold spike interneurons (Conn et al., 2005; Gubellini et al., 2004). On SPNs, mGluR5 and NMDA receptors are tethered by scaffolding proteins and activation of mGluR5 receptors amplifies NMDA receptor-mediated currents (Conn et al., 2005; Pisani et al., 2001). On indirect SPNs, mGluR5 receptors physically interact with A_{2A} adenosine receptors to synergistically promote MAPK signaling, thereby counteracting the effect of D2 receptor activation (Ferre et al., 2002; Nishi et al., 2003). Further, Group I mGluRs are expressed on cell bodies and terminals of dopaminergic neurons from the SNc (Conn et al., 2005; Hubert et al., 2001). Outside of the striatum, Group I mGluRs are expressed on GABAergic neurons located in the globus pallidus and SNr.

Given the broad distribution of mGluRs in the basal ganglia, mGluR5 negative allosteric modulators (NAMs) have been proposed as a new therapeutic in dystonia. One study in Dyt1 knockin mice showed that the mGluR5 NAM ADX48621 restores normal responses to D2 receptor activation of striatal ChIs (Sciamanna et al., 2014). Neither mGluR5 NAMs nor antagonists have been tested in dystonia patients, but tests in both animals models of LIDS and patients with LIDs have shown promising results (Bezard et al., 2014; Dekundy et al., 2011; Tison et al., 2016). Future studies examining metabotropic glutamate receptors in dystonia will be aided by the recent discovery of a number of subtype-selective mGluR negative and positive allosteric modulators (Bollinger et al., 2017; Nickols et al., 2016; Panarese et al., 2019; Reed et al., 2019).

5.5. NMDA receptor antagonists

Inotropic glutamate receptors are subdivided into three classes named according to their affinity for their selective agonists: α -amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), kainic acid or kainate (KA), and N-methyl-D-aspartate (NMDA) (Traynelis et al., 2010). NMDA receptor antagonists have been most extensively studied for treatment of dystonia. NMDA receptor complexes are composed of NR1, NR2A-D and NR3A-B subunits (Kew and Kemp, 2005). The NR1 subunit is expressed ubiquitously throughout the brain, whereas the NR2 subunits have regional patterns of distribution and confer distinct electrophysiological and pharmacological properties to NMDA receptor complexes (Traynelis et al., 2010). In the adult brain, striatal SPNs are enriched for NR2A and NR2B subunits (Dunah and Standaert, 2003; Goebel and Poosch, 1999; Kosinski et al., 1998; Landwehrmeyer et al., 1995; Monyer et al., 1994; Smeal et al., 2008; Standaert et al., 1994). In contrast, the globus pallidus and STN primarily express NR2A and NR2D subunits (Wenzel et al., 1997; Wenzel et al., 1996).

NMDA receptor antagonists, such as amantadine, are sometimes used to treat dystonia (Borison, 1983; Gilbert, 1971). The use of amantadine is limited due to significant side effects including: constipation, cardiovascular dysfunction, hallucinations, delirium, and anxiety (Perez-Lloret and Rascol, 2018). In Dyt1 knockin mice, there is a selective increase in NR2A, but not NR2B, subunits at striatal postsynaptic sites (Maltese et al., 2018). In the dt^{sz} hamster, an NR2A-preferring antagonist improved dystonia, while NR2B-preferring antagonist worsened dystonia (Avchalumov et al., 2014; Richter, 2003). Additional studies in the dt^{sz} hamster found that antagonists with equal affinity for NR2A/NR2B produced moderate improvement (Sander and Richter, 2007). Interestingly, this is in agreement with studies in rodent models of LIDs, in which NR2A-preferring antagonists were effective in reducing abnormal movements (Gardoni et al., 2012), while NR2B-preferring antagonists exacerbated abnormal movements (Nash et al., 2004). These studies suggest that more selective NR2A-preferring antagonists, or even NAMs, might be effective therapeutics for dystonia and could reduce some of the negative side effects that limit the use of nonselective NMDA receptor antagonists. NMDA receptor antagonists have not been tested in dystonia patients. However, one clinical trial found that the NR2B selective NMDA receptor antagonist MK-0657 did not improve dyskinesias or motor symptoms in patients with Parkinson's disease, which agrees with preclinical studies (Herring et al., 2017).

5.6. Adenosine A_{2A} receptor antagonists

Adenosine acts on two different G-protein coupled receptors within the basal ganglia: A₁ and A_{2A}. A₁ adenosine receptors are located presynaptically on corticostriatal afferents, and postsynaptically on striatonigral and striatopallidal SPNs as well as ChIs (Alexander and Reddington, 1989; Fastbom et al., 1987; Ferre et al., 1996; Preston, 2000). Activation of G $\alpha_{i/o}$ -coupled A₁ adenosine receptors decreases cAMP levels, increases K⁺ conductance, and decreases transient Ca²⁺ levels (Ambrosio et al., 1996), thereby decreasing the likelihood of neurotransmitter release from presynaptic terminals (Fredholm, 1995). A_{2A} adenosine receptors are selectively expressed on striatopallidal SPNs and ChIs (Fink et al., 1992; Preston et al., 2000; Schiffmann et al., 1991). Activation of G α_{oif} -coupled A_{2A} adenosine receptors increases cAMP levels, activating PKA and MAPK signaling (Schulte and Fredholm, 2003). Interestingly, A_{2A} adenosine receptors also form heteromeric complexes with D2 receptors (Canals et al., 2003; Ferre et al., 2008; Fuxe et al., 2005; Hillion et al., 2002) and mGluR5s (Ferre et al., 2002; Morelli et al., 2007).

Studies in animal models suggest A_{2A} adenosine receptor antagonists may be effective therapeutics. A_{2A} adenosine receptor antagonists restore normal patterns of corticostriatal plasticity in Dyt1 (Napolitano et al., 2010) and Dyt11 mice (Maltese et al., 2017). In contrast, studies

in the dt^{sz} hamster showed that A₁- and A_{2A}-selective adenosine receptor agonists improved dystonia, while nonselective adenosine receptor antagonists worsened dystonia. A_{2A}-selective adenosine receptor antagonists had no effect on dystonia severity in these hamsters (Richter and Hamann, 2001). Clinical trials using adenosine receptor compounds have not been conducted in dystonia patients. However, A_{2A} adenosine receptor antagonists have been investigated in animal models of Parkinson's disease and produce limited improvement in dyskinesia symptoms in clinical trials (LeWitt et al., 2008; Nunez et al., 2018; Wang et al., 2017).

5.7. Cannabinoid receptor agonists

Most research has focused on type 1 (CB₁) and type 2 (CB₂) cannabinoid receptors. Both receptors are coupled to G $\alpha_{i/o}$ and are activated by retrograde signaling of the endocannabinoids arachidonoyl ethanolamide (anandamide or AEA) and 2-arachidonoyl glycerol (2-AG) (Freund et al., 2003; Kreitzer and Malenka, 2005; Mechoulam and Parker, 2013; Tanimura et al., 2010). The CB₁ receptor is densely expressed in the striatum (Fusco et al., 2004; Herkenham et al., 1991; Matyas et al., 2006). CB₁ receptors are localized to corticostriatal terminals, where they modulate cortical excitation of SPNs (Gerdeman and Lovinger, 2001; Wu et al., 2015). Additionally, CB₁ receptors are robustly expressed on SPN axon terminals and have also been observed on striatal parvalbumin-containing GABA interneurons (Hohmann and Herkenham, 2000; Uchigashima et al., 2007). Unlike the CB₁ receptor, the CB₂ receptor was historically considered a peripheral cannabinoid receptor. However, the CB₂ receptor is also expressed in the striatum and globus pallidus, albeit at significantly lower levels of expression than the CB₁ receptor (Callen et al., 2012; Gong et al., 2006; Lanciego et al., 2011). A recent study found that CB₂ receptors are expressed on striatal DA terminals and decrease striatal DA release through retrograde endocannabinoid signaling (Foster et al., 2016).

There has been significant interest in endocannabinoids in the treatment of movement disorders (Kluger et al., 2015; Koppel, 2015; Lim et al., 2017; Peres et al., 2018; Saft et al., 2018). Two studies in the dt^{sz} hamster model of dystonia found that the CB₁/CB₂ receptor agonist WIN 55,212-2 alleviated dystonia, and this effect was blocked by a CB₁ receptor-specific antagonist (Richter and Loscher, 1994; Richter and Loscher, 2002). While animal studies have been generally positive, the few clinical trials and case reports in dystonia have been mixed. No improvement was observed in response to the CB₁/CB₂ receptor agonist nabilone (Fox et al., 2002), and another small placebo-controlled trial found no improvement for cervical dystonia in response to the CB₁/CB₂ agonist dronabinol (Zadikoff et al., 2011). However, an earlier study found significant improvement with the CB₁/CB₂ partial agonist cannabidiol in a small open-label trial (Consroe et al., 1986). Given the limited size of past clinical trials and inconsistency in results, further exploration of endocannabinoids for the treatment of dystonia is warranted.

5.8. Synaptic vesicle protein 2A (SV2A) modulators

SV2A modulators, including levetiracetam, were originally developed for epilepsy, but studies in rodents and humans have suggested therapeutic potential in dystonia. Levetiracetam is specific to the synaptic vesicle associated protein SV2A, which is found in all neurons in the CNS (Bajjalieh et al., 1993). Levetiracetam is thought to modulate the function of SV2A to reduce neurotransmitter release (Lynch et al., 2004). Several different SV2A modulators, including levetiracetam, improve dystonia in the dt^{sz} hamster model (Hamann et al., 2008; Loscher and Richter, 2000). However, the exact mechanism of action of levetiracetam in dystonia is unknown. One possibility is that SV2A modulators reduce cortical excitability, because an increase in cortical excitability is observed in multiple forms of dystonia in humans (Calabresi et al., 2016; Erro et al., 2018; Furuya et al., 2018; Hallett,

2006).

Results of clinical trials and case studies with SV2A modulators have been mixed. In two small clinical trials, levetiracetam was ineffective in patients with cranial/oromandibular or segmental/generalized dystonia (Hering et al., 2007; Park et al., 2017). However, in two different case reports, levetiracetam improved dystonia in two patients, one with generalized dystonia (Sullivan et al., 2005) and the other with Meige syndrome (Yardimci et al., 2006). Given the limited size of past clinical trials and inconsistency in results, further exploration of SV2A modulators in dystonia treatment is warranted. The prospect of using SV2A modulators or other compounds that modulate synaptic vesicle release is especially interesting in light of the use of tetraabenazine, a VMAT2 blocker, for the treatment of some dystonias and other movement disorders (Swash et al., 1972). This suggests that modulating synaptic vesicle release, either globally with a SV2A modulator or more specifically with a drug targeted to more restricted vesicular proteins, may represent a future therapeutic approach to dystonia treatment.

5.9. eIF2 α signaling

Endoplasmic reticulum (ER) dysfunction and abnormal eukaryotic initiation factor α (eIF2 α) signaling have been linked to a variety of neurological conditions, including dystonia (Moon et al., 2018; Rittiner et al., 2016). eIF2 α is a required component for eukaryotic translation initiation and is tightly regulated by phosphorylation/dephosphorylation to control the rate of protein translation and prevent ER stress (Donnelly et al., 2013). Studies in human-derived iPSCs and mouse models of DYT1 dystonia have demonstrated that while torsinA is normally localized in the endoplasmic reticulum, mutant torsinA (torsinA- Δ E) is primarily localized in the nuclear envelope (Hewett et al., 2003; Oberlin et al., 2004; Vander Heyden et al., 2009). Further, ER protein processing and eIF2 α signaling is abnormal in Dyt1 knockin mice and transgenic Dyt1 rats which suggests that neurons carrying the mutation in TorsinA may be highly susceptible to ER stress (Beauvais et al., 2016; Beauvais et al., 2018, 2019). Genetic studies in patients with sporadic cervical dystonia and DYT16 have revealed mutations in proteins involved in eIF2 α signaling (Rittiner et al., 2016). Furthermore, a recent study in DYT6 (THAP1) mice has also demonstrated abnormal eIF2 α signaling (Zakirova et al., 2018), which suggests that eIF2 α signaling might be a common dysfunction in multiple forms of dystonia. Importantly, pharmacologically modifying eIF2 α signaling with the eIF2 α dephosphorylation inhibitor salubrinal rescued both abnormal torsinA localization and abnormal ER function (Rittiner et al., 2016). Taken together, these studies support eIF2 α as a druggable target in dystonia.

5.10. Phosphodiesterase inhibitors (PDE10A)

Phosphodiesterases are responsible for terminating cellular cAMP and cGMP signaling. Accordingly, PDE inhibitors are expected to increase neuronal activity in the brain by enhancing cAMP and cGMP signaling. PDE10A is of specific interest to movement disorders because it is highly expressed throughout the basal ganglia, including direct and indirect pathway SPNs (Svedberg et al., 2019). A recent study in a transgenic mouse model of DYT1 dystonia found inverse changes in PDE10A expression in direct and indirect pathway SPNs (D'Angelo et al., 2017). PDE10A expression was decreased in direct SPNs, but increased in indirect SPNs. These changes are consistent with increased activation of the direct striatonigral pathway and reduced activity in the indirect striatopallidal pathway. There are no clinical trials of PDE10A inhibitors in dystonia. However, PDE10A inhibitors improve motor abnormalities in a mouse model of Huntington's disease and a non-human primate model of LIDs (Beaumont et al., 2016; Beck et al., 2018). Future studies are needed to determine if PDE10A inhibition modifies dystonia.

5.11. Brain derived neurotrophic growth factor (BDNF)

Brain derived neurotrophic growth factor (BDNF) is a widely distributed neurotrophin in the mammalian brain. BDNF binds and activates TrkB to regulate a variety of cellular processes related to neuronal and glial development and synaptic plasticity (Huang and Reichardt, 2001). Because of the importance of BDNF to neuronal plasticity, it is of significant interest in many neurodevelopmental diseases. A previous study has shown that, in early development, there is increased expression of BDNF in Dyt1 mice relative to WT littermates. This parallels the development of abnormal synaptic plasticity in Dyt1 mice and suggests a critical period for targeted intervention. *In vivo* administration of a TrkB inhibitor during this critical window rescued the abnormal synaptic plasticity, which identifies TrkB/BDNF signaling as a potential therapeutic target for DYT1 dystonia (Maltese et al., 2018). In the dt^{sz} hamster, changes in BDNF mRNA or protein expression were not detected (Bode et al., 2017). There is some evidence to suggest a polymorphism in the prodomain region of the BDNF gene may confer risk for developing cervical dystonia and/or blepharospasm (Chen et al., 2013; Siokas et al., 2018). The SNP rs6265 (G/A) (AF50.1896) results in the substitution of Val in amino acid position 66 with Met (val66met), and healthy carriers of the val66met have been reported to show differences in brain structure and abnormal motor cortex plasticity (Cheeran et al., 2008; Pezawas et al., 2004). However, a direct relationship between the val66met variant, abnormal motor cortex plasticity, and dystonia has yet to be uncovered. Taken together, these human genetics and preclinical studies support further investigation of TrkB/BDNF signaling as a potential therapeutic target in dystonia, as proposed for other neurological and psychiatric disorders (Deng et al., 2016; Longo et al., 2013; Nagahara et al., 2011).

6. Future directions for novel experimental therapeutics in dystonia

Despite advances in our understanding of the genetic and anatomical bases of dystonia, pathogenesis-targeting or disease-modifying therapies remain limited. While the limited oral therapeutics for dystonia are sometimes effective, patients often discontinue treatment due to dose-limiting side-effects, insufficient efficacy, or both. Recent advances in our understanding of the pathophysiological mechanisms of dystonia have revealed new therapeutic targets that deserve careful validation for clinical use. One challenge for drug discovery in dystonia is the heterogeneity of etiologies and disease presentations in the clinical population. The availability of a multitude of animal models for different forms of dystonia with construct and predictive validity will be instrumental for identifying promising common molecular targets. This, in turn, will facilitate clinical trials by identifying the most appropriate patient populations in which to test new, targeted therapies based on shared biological processes and molecular targets. Overall, recent advances in both basic and clinical research provide promising new platforms for the development of novel therapeutics.

Declarations of Competing Interest

None.

Acknowledgments

This work was supported by United States Department of Defense grant W81XWH-15-1-0545 and United States National Institute of Health Grants R01 NS 088528 F31 NS103363 and T32 GM008602 to EJH, and by the Italian Ministry of Health (Ricerca Corrente) to AP and PB. The authors are grateful for the support of the Dystonia Medical Research Foundation.

References

- Albanese, A., et al., 2013. Phenomenology and classification of dystonia: a consensus update. *Mov. Disord.* 28, 863–873.
- Albin, R.L., et al., 1989. The functional anatomy of basal ganglia disorders. *Trends Neurosci.* 12, 366–375.
- Alcantara, A.A., et al., 2001. Muscarinic m1 and m2 receptor proteins in local circuit and projection neurons of the primate striatum: anatomical evidence for cholinergic modulation of glutamatergic prefronto-striatal pathways. *J. Comp. Neurol.* 434, 445–460.
- Alexander, S.P., Reddington, M., 1989. The cellular localization of adenosine receptors in rat neostriatum. *Neuroscience.* 28, 645–651.
- Ambrosio, A.F., et al., 1996. Modulation of Ca²⁺ channels by activation of adenosine A1 receptors in rat striatal glutamatergic nerve terminals. *Neurosci. Lett.* 220, 163–166.
- Andersen, P.H., et al., 1990. Dopamine receptor subtypes: beyond the D1/D2 classification. *Trends Pharmacol. Sci.* 11, 231–236.
- Asanuma, K., et al., 2005a. Neuroimaging in human dystonia. *J. Med. Investig.* 52, 272–279 Suppl.
- Asanuma, K., et al., 2005b. Decreased striatal D2 receptor binding in non-manifesting carriers of the DYT1 dystonia mutation. *Neurology.* 64, 347–349.
- Avshalumov, Y., et al., 2014. Role of striatal NMDA receptor subunits in a model of paroxysmal dystonia. *Exp. Neurol.* 261, 677–684.
- Bajjalieh, S.M., et al., 1993. Brain contains two forms of synaptic vesicle protein 2. *Proc. Natl. Acad. Sci. U. S. A.* 90, 2150–2154.
- Bateup, H.S., et al., 2010. Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. *Proc. Natl. Acad. Sci. U. S. A.* 107, 14845–14850.
- Beaumont, V., et al., 2016. Phosphodiesterase 10A inhibition improves cortico-basal ganglia function in huntington's disease models. *Neuron.* 92, 1220–1237.
- Beauvais, G., et al., 2016. Disruption of protein processing in the endoplasmic reticulum of DYT1 knock-in mice implicates novel pathways in dystonia pathogenesis. *J. Neurosci.* 36, 10245–10256.
- Beauvais, G., et al., 2018. Exploring the interaction between eIF2 α dysregulation, acute endoplasmic reticulum stress and DYT1 dystonia in the mammalian brain. *Neuroscience.* 371, 455–468.
- Beauvais, G., et al., 2019 Mar 1. Efficient RNA interference-based knockdown of mutant torsinA reveals reversibility of PERK-eIF2 α pathway dysregulation in DYT1 transgenic rats in vivo. *Brain Res.* 1706, 24–31.
- Beck, G., et al., 2018. A selective phosphodiesterase 10A inhibitor reduces L-Dopa-Induced dyskinesias in parkinsonian monkeys. *Mov. Disord.* 33, 805–814.
- Bender, A.M., et al., 2018. Discovery and optimization of potent and CNS penetrant M5-prefering positive allosteric modulators derived from a novel, Chiral N-(Indanyl) piperidine amide scaffold. *ACS Chem. Neurosci.* 9, 1572–1581.
- Berman, B.D., et al., 2013. Striatal dopaminergic dysfunction at rest and during task performance in writer's cramp. *Brain.* 136, 3645–3658.
- Bezard, E., et al., 2014. The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. *Mov. Disord.* 29, 1074–1079.
- Bhatia, K.P., Marsden, C.D., 1994. The behavioural and motor consequences of focal lesions of the basal ganglia in man. *Brain.* 117, 859–876 Pt 4.
- Blood, A.J., et al., 2004. Basal ganglia activity remains elevated after movement in focal hand dystonia. *Ann. Neurol.* 55, 744–748.
- Bode, C., et al., 2017. Altered postnatal maturation of striatal GABAergic interneurons in a phenotypic animal model of dystonia. *Exp. Neurol.* 287, 44–53.
- Bollinger, K.A., et al., 2017. Design and synthesis of mGlu2 NAMs with improved potency and CNS penetration based on a truncated picolinamide core. *ACS Med. Chem. Lett.* 8, 919–924.
- Bologna, M., Berardelli, A., 2018. The cerebellum and dystonia. *Handb. Clin. Neurol.* 155, 259–272.
- Bonsi, P., et al., 2008. Loss of muscarinic autoreceptor function impairs long-term depression but not long-term potentiation in the striatum. *J. Neurosci.* 28, 6258–6263.
- Bonsi, P., et al., 2011. Centrality of striatal cholinergic transmission in basal ganglia function. *Front. Neuroanat.* 5.
- Bonsi, P., et al., 2019 Jan. RGS9-2 rescues dopamine D2 receptor levels and signaling in DYT1 dystonia mouse models. *EMBO Mol Med.* 11 (1).
- Borison, R.L., 1983. Amantadine in the management of extrapyramidal side effects. *Clin. Neuropharmacol.* 6 (Suppl. 1), S57–S63.
- Bostan, A.C., et al., 2010. The basal ganglia communicate with the cerebellum. *Proc. Natl. Acad. Sci. U. S. A.* 107, 8452–8456.
- Bostan, A.C., et al., 2018. The basal ganglia and the cerebellum: nodes in an integrated network. *Nat. Rev. Neurosci.* 19, 338–350.
- Brimblecombe, K.R., et al., 2018. Targeted activation of cholinergic interneurons accounts for the modulation of dopamine by striatal nicotinic receptors. *eNeuro.* 5.
- Brun, L., et al., 2010. Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. *Neurology.* 75, 64–71.
- Burke, R.E., et al., 1986. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. *Neurology.* 36, 160–164.
- Bymaster, F.P., et al., 2003. Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. *Eur. J. Neurosci.* 17, 1403–1410.
- Cai, Y., Ford, C.P., 2018. Dopamine cells differentially regulate striatal cholinergic transmission across regions through corelease of dopamine and glutamate. *Cell Rep.* 25, 3148–3157.e3.
- Calabresi, P., et al., 2016. Hyperkinetic disorders and loss of synaptic downscaling. *Nat. Neurosci.* 19, 868–875.
- Calderon, D.P., et al., 2011. The neural substrates of rapid-onset Dystonia-Parkinsonism. *Nat. Neurosci.* 14, 357–365.
- Callen, L., et al., 2012. Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. *J. Biol. Chem.* 287, 20851–20865.
- Camfield, L., et al., 2002. Impact of cervical dystonia on quality of life. *Mov. Disord.* 17, 838–841.
- Campbell, D.B., et al., 1999. Tottering mouse motor dysfunction is abolished on the Purkinje cell degeneration (pcd) mutant background. *Exp. Neurol.* 160, 268–278.
- Canals, M., et al., 2003. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. *J. Biol. Chem.* 278, 46741–46749.
- Carbon, M., et al., 2004. Regional metabolism in primary torsion dystonia: effects of penetrance and genotype. *Neurology.* 62, 1384–1390.
- Carbon, M., et al., 2013. Metabolic changes in DYT11 myoclonus-dystonia. *Neurology.* 80, 385–391.
- Cheeran, B., et al., 2008. A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS. *J. Physiol.* 586, 5717–5725.
- Chen, Y., et al., 2013. Association of the Val66Met polymorphism of the BDNF gene with primary cranial-cervical dystonia patients from South-west China. *Parkinsonism Relat. Disord.* 19, 1043–1045.
- Cloud, L.J., Jinnah, H.A., 2010. Treatment strategies for dystonia. *Expert. Opin. Pharmacother.* 11, 5–15.
- Conn, P.J., Pin, J.P., 1997. Pharmacology and functions of metabotropic glutamate receptors. *Annu. Rev. Pharmacol. Toxicol.* 37, 205–237.
- Conn, P.J., et al., 2005. Metabotropic glutamate receptors in the basal ganglia motor circuit. *Nat. Rev. Neurosci.* 6, 787–798.
- Consroe, P., et al., 1986. Open label evaluation of cannabidiol in dystonic movement disorders. *Int J Neurosci.* 30, 277–282.
- Corvol, J.C., et al., 2001. Galpha(olf) is necessary for coupling D1 and A2a receptors to adenylyl cyclase in the striatum. *J. Neurochem.* 76, 1585–1588.
- Cui, G., et al., 2013. Concurrent activation of striatal direct and indirect pathways during action initiation. *Nature.* 494, 238–242.
- Dang, M.T., et al., 2012. An anticholinergic reverses motor control and corticostriatal LTD deficits in Dyt1 DeltaGAG knock-in mice. *Behav. Brain Res.* 226, 465–472.
- D'Angelo, V., et al., 2017. Phosphodiesterase-10A inverse changes in striatopallidal and striatoentopeduncular pathways of a transgenic mouse model of DYT1 dystonia. *J. Neurosci.* 37, 2112–2124.
- Dautan, D., et al., 2016. Extrinsic sources of cholinergic innervation of the striatal complex: a whole-brain mapping analysis. *Front. Neuroanat.* 10, 1.
- Dawson, V.L., et al., 1990. Muscarinic and dopaminergic receptor subtypes on striatal cholinergic interneurons. *Brain Res. Bull.* 25, 903–912.
- De Mei, C., et al., 2009. Getting specialized: presynaptic and postsynaptic dopamine D2 receptors. *Curr. Opin. Pharmacol.* 9, 53–58.
- Defazio, G., 2010. The epidemiology of primary dystonia: current evidence and perspectives. *Eur. J. Neurol.* 17 (Suppl. 1), 9–14.
- Dekundy, A., et al., 2011. Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L-DOPA-induced dyskinesia. *J. Neural Transm. (Vienna)* 118, 1703–1716.
- DeLong, M.R., 1990. Primate models of movement disorders of basal ganglia origin. *Trends Neurosci.* 13, 281–285.
- Deng, P., et al., 2016. Engineered BDNF producing cells as a potential treatment for neurologic disease. *Expert. Opin. Biol. Ther.* 16, 1025–1033.
- Donnelly, N., et al., 2013. The eIF2 α kinases: their structures and functions. *Cell. Mol. Life Sci.* 70, 3493–3511.
- Downs, A.M., et al., 2019. Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia. *Neurobiol. Dis.* 125, 115–122.
- Draganski, B., et al., 2003. "Motor circuit" gray matter changes in idiopathic cervical dystonia. *Neurology.* 61, 1228–1231.
- Draganski, B., et al., 2009. Genotype-phenotype interactions in primary dystonias revealed by differential changes in brain structure. *Neuroimage.* 47, 1141–1147.
- Dunah, A.W., Standaert, D.G., 2003. Subcellular segregation of distinct heteromeric NMDA glutamate receptors in the striatum. *J. Neurochem.* 85, 935–943.
- Durieux, P.F., et al., 2009. D2R striatopallidal neurons inhibit both locomotor and drug reward processes. *Nat. Neurosci.* 12, 393–395.
- Egger, K., et al., 2007. Voxel based morphometry reveals specific gray matter changes in primary dystonia. *Mov. Disord.* 22, 1538–1542.
- Eidelberg, D., et al., 1998. Functional brain networks in DYT1 dystonia. *Ann. Neurol.* 44, 303–312.
- Erro, R., et al., 2018. High frequency somatosensory stimulation in dystonia: evidence for defective inhibitory plasticity. *Mov. Disord.* 33, 1902–1909.
- Eskow Jaunarajs, K.L., et al., 2015. Striatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystonia. *Prog. Neurobiol.* 127–128, 91–107.
- Exley, R., et al., 2008. Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. *Neuropsychopharmacology.* 33, 2158–2166.
- Fahn, S., 1983. High-dosage anticholinergic therapy in dystonia. *Adv. Neurol.* 37, 177–188.
- Fan, X., et al., 2018. Dopamine receptor agonist treatment of idiopathic dystonia: a reappraisal in humans and mice. *J. Pharmacol. Exp. Ther.* 365, 20–26.
- Fastbom, J., et al., 1987. Adenosine A1 receptors in the human brain: a quantitative autoradiographic study. *Neuroscience.* 22, 827–839.
- Ferre, S., et al., 1996. Dopamine D1 receptor-mediated facilitation of GABAergic neurotransmission in the rat striatopallidum pathway and its modulation by adenosine A1 receptor-mediated mechanisms. *Eur. J. Neurosci.* 8, 1545–1553.
- Ferre, S., et al., 2002. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. *Proc. Natl. Acad. Sci. U. S. A.* 99, 11940–11945.

- Ferre, S., et al., 2008. An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. *Curr. Pharm. Des.* 14, 1468–1474.
- Filip, P., et al., 2017. Disruption in cerebellar and basal ganglia networks during a visuospatial task in cervical dystonia. *Mov. Disord.* 32, 757–768.
- Fink, J.S., et al., 1992. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. *Brain Res. Mol. Brain Res.* 14, 186–195.
- Foster, D.J., et al., 2014. M5 receptor activation produces opposing physiological outcomes in dopamine neurons depending on the receptor's location. *J. Neurosci.* 34, 3253–3262.
- Foster, D.J., et al., 2016. Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release. *Neuron.* 91, 1244–1252.
- Fox, S.H., et al., 2002. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. *Mov. Disord.* 17, 145–149.
- Fredholm, B.B., 1995. Purinoceptors in the nervous system. *Pharmacol. Toxicol.* 76, 228–239.
- Frei, K.P., et al., 2004. Natural history of posttraumatic cervical dystonia. *Mov. Disord.* 19, 1492–1498.
- Fremont, R., et al., 2017. A role for cerebellum in the hereditary dystonia DYT1. *Elife.* 6.
- Freund, T.F., et al., 2003. Role of endogenous cannabinoids in synaptic signaling. *Physiol. Rev.* 83, 1017–1066.
- Furukawa, Y., et al., 1996. GTP-cyclohydrolase I gene mutations in hereditary progressive and dopa-responsive dystonia. *Ann. Neurol.* 39, 609–617.
- Furuya, S., et al., 2018. Aberrant cortical excitability reflects the loss of hand dexterity in musician's dystonia. *J. Physiol.* 596, 2397–2411.
- Fusco, F.R., et al., 2004. Immunolocalization of CB1 receptor in rat striatal neurons: a confocal microscopy study. *Synapse.* 53, 159–167.
- Fuxe, K., et al., 2005. Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function. *J. Mol. Neurosci.* 26, 209–220.
- Gainetdinov, R.R., et al., 1996. In vivo evidence for preferential role of dopamine D3 receptor in the presynaptic regulation of dopamine release but not synthesis. *Eur. J. Pharmacol.* 308, 261–269.
- Galardi, G., et al., 1996. Basal ganglia and thalamo-cortical hypermetabolism in patients with spasmodic torticollis. *Acta Neurol. Scand.* 94, 172–176.
- Gardoni, F., et al., 2012. Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias. *Neurobiol. Aging* 33, 2138–2144.
- Gerdeman, G., Lovinger, D.M., 2001. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. *J. Neurophysiol.* 85, 468–471.
- Gerfen, C.R., 2000. Molecular effects of dopamine on striatal-projection pathways. *Trends Neurosci.* 23, S64–S70.
- Gilbert, G.J., 1971. Spasmodic torticollis treated effectively by medical means. *N. Engl. J. Med.* 284, 896–898.
- Girasole, A.E., Nelson, A.B., 2015. Bridging the Gap: muscarinic M4 receptors promote striatal plasticity in health and disease. *Neuron.* 88, 621–623.
- Giros, B., et al., 1989. Alternative splicing directs the expression of two D2 dopamine receptor isoforms. *Nature.* 342, 923–926.
- Gittis, A.H., et al., 2010. Distinct roles of GABAergic interneurons in the regulation of striatal output pathways. *J. Neurosci.* 30, 2223–2234.
- Goebel, D.J., Poosch, M.S., 1999. NMDA receptor subunit gene expression in the rat brain: a quantitative analysis of endogenous mRNA levels of NR1Com, NR2A, NR2B, NR2C, NR2D and NR3A. *Brain Res. Mol. Brain Res.* 69, 164–170.
- Gong, J.P., et al., 2006. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. *Brain Res.* 1071, 10–23.
- Gonzales, K.K., Smith, Y., 2015. Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions. *Ann. N. Y. Acad. Sci.* 1349, 1–45.
- Gomati, S.V., et al., 2018. Differentiating cerebellar impact on thalamic nuclei. *Cell Rep.* 23, 2690–2704.
- Greene, P., et al., 1988. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. *Mov. Disord.* 3, 46–60.
- Grenhoff, J., et al., 1986. Nicotinic effects on the firing pattern of midbrain dopamine neurons. *Acta Physiol. Scand.* 128, 351–358.
- Gritton, H.J., et al., 2019. Unique contributions of parvalbumin and cholinergic interneurons in organizing striatal networks during movement. *Nat. Neurosci.* 22, 586–597.
- Gubellini, P., et al., 2004. Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases. *Prog. Neurobiol.* 74, 271–300.
- Hallett, M., 2006. Pathophysiology of dystonia. *J. Neural Transm. Suppl.* 485–488.
- Hamann, M., et al., 2008. Brivaracetam and seletacetam, two new SV2A ligands, improve paroxysmal dystonia in the dt sz mutant hamster. *Eur. J. Pharmacol.* 601, 99–102.
- Hamann, M., et al., 2017. Alterations of M1 and M4 acetylcholine receptors in the genetically dystonic (dt(sz)) hamster and moderate antidystonic efficacy of M1 and M4 anticholinergics. *Neuroscience.* 357, 84–98.
- Harrison, M.B., et al., 1996. Expression of m1 and m4 muscarinic receptor mRNA in the striatum following a selective lesion of striatonigral neurons. *Brain Res.* 734, 323–326.
- Haslinger, B., et al., 2010. Sensorimotor overactivity as a pathophysiologic trait of embouchure dystonia. *Neurology.* 74, 1790–1797.
- Hering, S., et al., 2007. An open trial of levitracetam for segmental and generalized dystonia. *Mov. Disord.* 22, 1649–1651.
- Herkenham, M., et al., 1991. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. *Brain Res.* 547, 267–274.
- Hernandez-Flores, T., et al., 2015. Modulation of direct pathway striatal projection neurons by muscarinic M(4)-type receptors. *Neuropharmacology.* 89, 232–244.
- Herring, W.J., et al., 2017. A phase Ib randomized controlled study to evaluate the effectiveness of a single-dose of the NR2B selective N-Methyl-D-Aspartate antagonist MK-0657 on levodopa-induced dyskinesias and motor symptoms in patients with Parkinson disease. *Clin. Neuropharmacol.* 40, 255–260.
- Hewett, J., et al., 2003. TorsinA in PC12 cells: localization in the endoplasmic reticulum and response to stress. *J. Neurosci. Res.* 72, 158–168.
- Hillion, J., et al., 2002. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. *J. Biol. Chem.* 277, 18091–18097.
- Hohmann, A.G., Herkenham, M., 2000. Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. *Synapse.* 37, 71–80.
- Hoshi, E., et al., 2005. The cerebellum communicates with the basal ganglia. *Nat. Neurosci.* 8, 1491–1493.
- Huang, E.J., Reichardt, L.F., 2001. Neurotrophins: roles in neuronal development and function. *Annu. Rev. Neurosci.* 24, 677–736.
- Hubert, G.W., et al., 2001. Differential subcellular localization of mGluR1a and mGluR5 in the rat and monkey Substantia nigra. *J. Neurosci.* 21, 1838–1847.
- Huntley, G.W., et al., 1992. Localization of multiple dopamine receptor subtype mRNAs in human and monkey motor cortex and striatum. *Brain Res. Mol. Brain Res.* 15, 181–188.
- Ichinose, H., et al., 1995. GTP cyclohydrolase I gene in hereditary progressive dystonia with marked diurnal fluctuation. *Neurosci. Lett.* 196, 5–8.
- Ichinose, H., et al., 2000. Molecular mechanisms of hereditary progressive dystonia with marked diurnal fluctuation, Segawa's disease. *Brain Dev.* 22 (Suppl. 1), S107–S110.
- Jabbari, B., et al., 1989. Treatment of movement disorders with trihexyphenidyl. *Mov. Disord.* 4, 202–212.
- Jinnah, H.A., et al., 2017. The Anatomical Basis for Dystonia: The Motor Network Model. *Tremor Other Hyperkinet Mov (N Y).* 7, 506.
- Karimi, M., Perlmutter, J.S., 2015. The role of dopamine and dopaminergic pathways in dystonia: insights from neuroimaging. *Tremor Other Hyperkinet Mov (N Y).* 5, 280.
- Kawaguchi, Y., 1993. Physiological, morphological, and histochemical characterization of three classes of interneurons in rat neostriatum. *J. Neurosci.* 13, 4908–4923.
- Kawaguchi, Y., 1997. Neostriatal cell subtypes and their functional roles. *Neurosci. Res.* 27, 1–8.
- Kebabian, J.W., Calne, D.B., 1979. Multiple receptors for dopamine. *Nature.* 277, 93–96.
- Kew, J.N., Kemp, J.A., 2005. Ionotropic and metabotropic glutamate receptor structure and pharmacology. *Psychopharmacology* 179, 4–29.
- Kluger, B., et al., 2015. The therapeutic potential of cannabinoids for movement disorders. *Mov. Disord.* 30, 313–327.
- Koppel, B.S., 2015. Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics. *Neurotherapeutics.* 12, 788–792.
- Kosillo, P., et al., 2016 Oct. Cortical Control of Striatal Dopamine Transmission via Striatal Cholinergic Interneurons. *Cereb. Cortex* 26 (11), 4160–4169.
- Kosinski, C.M., et al., 1998. Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: striatum and globus pallidus. *J. Comp. Neurol.* 390, 63–74.
- Krauss, J.K., Jankovic, J., 2002. Head injury and posttraumatic movement disorders. *Neurosurgery.* 50, 927–939 discussion 939–40.
- Kravitz, A.V., et al., 2010. Regulation of parkinsonian motor behaviors by optogenetic control of basal ganglia circuitry. *Nature.* 466, 622–626.
- Kreitzer, A.C., Malenka, R.C., 2005. Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. *J. Neurosci.* 25, 10537–10545.
- Krienen, F.M., Buckner, R.L., 2009. Segregated fronto-cerebellar circuits revealed by intrinsic functional connectivity. *Cereb. Cortex* 19, 2485–2497.
- Kurian, M.A., et al., 2011. Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. *Lancet Neurol.* 10, 54–62.
- Lanciego, J.L., et al., 2011. Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis. *J. Psychopharmacol.* 25, 97–104.
- Landwehrmeyer, G.B., et al., 1995. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. *J. Neurosci.* 15, 5297–5307.
- Lang, A.E., 1986. High dose anticholinergic therapy in adult dystonia. *Can J Neurol Sci.* 13, 42–46.
- Lang, A.E., et al., 1982. Anticholinergics in adult-onset focal dystonia. *Can J Neurol Sci.* 9, 313–319.
- LeDoux, M.S., 2011. Animal models of dystonia: Lessons from a mutant rat. *Neurobiol. Dis.* 42, 152–161.
- LeDoux, M.S., Brady, K.A., 2003. Secondary cervical dystonia associated with structural lesions of the central nervous system. *Mov. Disord.* 18, 60–69.
- Lees, A.J., 1984. Hemidystonia relieved by nicotine. *Lancet.* 2, 871.
- Lehericy, S., et al., 2013. The anatomical basis of dystonia: current view using neuroimaging. *Mov. Disord.* 28, 944–957.
- Lewis, L.M., et al., 2008. Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists. *Bioorg. Med. Chem. Lett.* 18, 885–890.
- LeWitt, P.A., et al., 2008. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). *Ann. Neurol.* 63, 295–302.
- Lim, K., et al., 2017. A systematic review of the effectiveness of medical cannabis for psychiatric, Movement and neurodegenerative disorders. *Clin Psychopharmacol Neurosci.* 15, 301–312.
- Lloyd, K.G., et al., 1981. Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. *N. Engl. J. Med.* 305, 1106–1111.
- Lo, S.E., et al., 2005. Identification and treatment of cervical and oromandibular dystonia in acutely brain-injured patients. *Neurocrit. Care.* 3, 139–145.

- Longo, F.M., et al., 2013. Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease. *Nat. Rev. Drug Discov.* 12, 507–525.
- Lopez-Arizegui, N., et al., 2009. Central levodopa influx and the clinical motor response to levodopa in patients with Parkinson disease complicated with motor fluctuations and dyskinesias. *Clin. Neuropharmacol.* 32, 321–325.
- Loscher, W., Richter, A., 2000. Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia. *Eur. J. Pharmacol.* 391, 251–254.
- Louis, E.D., et al., 1999. Dystonia in Huntington's disease: prevalence and clinical characteristics. *Mov. Disord.* 14, 95–101.
- Lozano, A.M., et al., 1997. Globus pallidus internus pallidotomy for generalized dystonia. *Mov. Disord.* 12, 865–870.
- Lumsden, D.E., et al., 2016. Medication use in childhood dystonia. *Eur. J. Paediatr. Neurol.* 20, 625–629.
- Lynch, B.A., et al., 2004. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. *Proc. Natl. Acad. Sci. U. S. A.* 101, 9861–9866.
- Mahmoudi, S., et al., 2014. Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model. *Mov. Disord.* 29, 1125–1133.
- Maltese, M., et al., 2014. Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: role of M1 muscarinic receptors. *Mov. Disord.* 29, 1655–1665.
- Maltese, M., et al., 2017. Abnormal striatal plasticity in a DYT11/SGCE myoclonus dystonia mouse model is reversed by adenosine A2A receptor inhibition. *Neurobiol. Dis.* 108, 128–139.
- Maltese, M., et al., 2018. Early structural and functional plasticity alterations in a susceptibility period of DYT1 dystonia mouse striatum. *Elife.* 7.
- Marlo, J.E., et al., 2009. Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. *Mol. Pharmacol.* 75, 577–588.
- Martella, G., et al., 2009. Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine. *Brain.* 132, 2336–2349.
- Martella, G., et al., 2014. Regional specificity of synaptic plasticity deficits in a knock-in mouse model of DYT1 dystonia. *Neurobiol. Dis.* 65, 124–132.
- Matyas, F., et al., 2006. Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. *Neuroscience.* 137, 337–361.
- Mechoulam, R., Parker, L.A., 2013. The endocannabinoid system and the brain. *Annu. Rev. Psychol.* 64, 21–47.
- Micheli, F., Fernandez Pardo, M.M., 1986. Responses to lisuride in Meige's disease and chorea. *Neurology.* 36, 445.
- Micheli, F., et al., 1982 Apr. Beneficial effects of lisuride in Meige disease. *Neurology.* 32 (4), 432–434.
- Missale, C., et al., 1998. Dopamine receptors: from structure to function. *Physiol. Rev.* 78, 189–225.
- Monsma Jr., F.J., et al., 1989. Multiple D2 dopamine receptors produced by alternative RNA splicing. *Nature.* 342, 926–929.
- Monyer, H., et al., 1994. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. *Neuron.* 12, 529–540.
- Moon, S.L., et al., 2018. Neuronal regulation of eIF2alpha function in health and neurological disorders. *Trends Mol. Med.* 24, 575–589.
- Morelli, M., et al., 2007. Role of adenosine A2A receptors in parkinsonian motor impairment and L-DOPA-induced motor complications. *Prog. Neurobiol.* 83, 293–309.
- Myerson, A., Loman, J., 1942. Amphetamine sulfate in treatment of spasmodic torticollis: report of two cases. *Arch. Neurol. Psychiatr.* 48, 823–828.
- Nagahara, A.H., et al., 2011. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. *Nat. Rev. Drug Discov.* 10, 209–219.
- Napolitano, F., et al., 2010. Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia. *Neurobiol. Dis.* 38, 434–445.
- Nash, J.E., et al., 2004. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. *Exp. Neurol.* 188, 471–479.
- Nemeth, A.H., 2002. The genetics of primary dystonias and related disorders. *Brain.* 125, 695–721.
- Neychev, V.K., et al., 2008. The basal ganglia and cerebellum interact in the expression of dystonic movement. *Brain.* 131, 2499–2509.
- Neychev, V.K., et al., 2011. The functional neuroanatomy of dystonia. *Neurobiol. Dis.* 42, 185–201.
- Nickols, H.H., et al., 2016. VU0477573: partial negative allosteric modulator of the subtype 5 metabotropic glutamate receptor with In Vivo Efficacy. *J. Pharmacol. Exp. Ther.* 356, 123–136.
- Nishi, A., et al., 2003. Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling. *Proc. Natl. Acad. Sci. U. S. A.* 100, 1322–1327.
- Niswender, C.M., Conn, P.J., 2010. Metabotropic glutamate receptors: physiology, pharmacology, and disease. *Annu. Rev. Pharmacol. Toxicol.* 50, 295–322.
- Niznik, H.B., Van Tol, H.H., 1992. Dopamine receptor genes: new tools for molecular psychiatry. *J. Psychiatry Neurosci.* 17, 158–180.
- Nunez, F., et al., 2018. PBF509, an adenosine A2A receptor antagonist with efficacy in rodent models of movement disorders. *Front. Pharmacol.* 9, 1200.
- Oberlin, S.R., et al., 2004. Development and anatomic localization of torsinA. *Adv. Neurol.* 94, 61–65.
- Obermann, M., et al., 2007. Morphometric changes of sensorimotor structures in focal dystonia. *Mov. Disord.* 22, 1117–1123.
- Ostrem, J.L., Starr, P.A., 2008. Treatment of dystonia with deep brain stimulation. *Neurotherapeutics.* 5, 320–330.
- Ostrem, J.L., et al., 2017. Subthalamic nucleus deep brain stimulation in isolated dystonia: a 3-year follow-up study. *Neurology.* 88, 25–35.
- Panarese, J.D., et al., 2019. The discovery of VU0652957 (VU2957, Valigluxax): SAR and DMPK challenges en route to an mGlu4 PAM development candidate. *Bioorg. Med. Chem. Lett.* 29, 342–346.
- Pancani, T., et al., 2014. M4 mAChR-mediated modulation of glutamatergic transmission at corticostriatal synapses. *ACS Chem. Neurosci.* 5, 318–324.
- Parent, A., Hazrati, L.N., 1995. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. *Brain Res. Brain Res. Rev.* 20, 91–127.
- Park, J.E., et al., 2017. Lack of efficacy of levetiracetam in oromandibular and cranial dystonia. *Acta Neurol. Scand.* 136, 103–108.
- Paulson, G., 1960. Procyclidine for dystonia caused by phenothiazine derivatives. *Dis. Nerv. Syst.* 21, 447–448.
- Peres, F.F., et al., 2018. Cannabidiol as a promising strategy to treat and prevent movement disorders? *Front. Pharmacol.* 9, 482.
- Perez-Lloret, S., Rascol, O., 2018. Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. *J. Neural Transm. (Vienna)* 125, 1237–1250.
- Perlmuter, J.S., Mink, J.W., 2004. Dysfunction of dopaminergic pathways in dystonia. *Adv. Neurol.* 94, 163–170.
- Pezawas, L., et al., 2004. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. *J. Neurosci.* 24, 10099–10102.
- Pisani, A., et al., 2001. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. *Neuroscience.* 106, 579–587.
- Pizoli, C.E., et al., 2002. Abnormal cerebellar signaling induces dystonia in mice. *J. Neurosci.* 22, 7825–7833.
- Preston, Z., et al., 2000. Adenosine receptor expression and function in rat striatal cholinergic interneurons. *Br. J. Pharmacol.* 130, 886–890.
- Prudente, C.N., et al., 2013. Neuropathology of cervical dystonia. *Exp. Neurol.* 241, 95–104.
- Prudente, C.N., et al., 2016. A functional magnetic resonance imaging study of head movements in cervical dystonia. *Front. Neurol.* 7, 201.
- Reed, C.W., et al., 2019 Feb 14. Discovery of an orally bioavailable and Central Nervous System (CNS) penetrant mGlu7 Negative Allosteric Modulator (NAM) in vivo tool compound: N-(2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962). *J. Med. Chem.* 62 (3), 1690–1695.
- Rice, M.E., Cragg, S.J., 2004. Nicotine amplifies reward-related dopamine signals in striatum. *Nat. Neurosci.* 7, 583–584.
- Richter, A., 2003. The NMDA receptor NR2B subtype selective antagonist Ro 25-6981 aggravates paroxysmal dyskinesia in the dt(sz) mutant. *Eur. J. Pharmacol.* 458, 107–110.
- Richter, A., Hamann, M., 2001. Effects of adenosine receptor agonists and antagonists in a genetic animal model of primary paroxysmal dystonia. *Br. J. Pharmacol.* 134, 343–352.
- Richter, A., Loscher, W., 1994. (+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters. *Eur. J. Pharmacol.* 264, 371–377.
- Richter, A., Loscher, W., 2002. Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia. *Eur. J. Pharmacol.* 454, 145–151.
- Rilstone, J.J., et al., 2013. Brain dopamine-serotonin vesicular transport disease and its treatment. *N. Engl. J. Med.* 368, 543–550.
- Rittiner, J.E., et al., 2016. Functional genomic analyses of mendelian and sporadic disease identify impaired eif2alpha signaling as a generalizable mechanism for dystonia. *Neuron.* 92, 1238–1251.
- Rivera, A., et al., 2002. Molecular phenotype of rat striatal neurons expressing the dopamine D5 receptor subtype. *Eur. J. Neurosci.* 16, 2049–2058.
- Rondou, P., et al., 2010. The dopamine D4 receptor: biochemical and signalling properties. *Cell. Mol. Life Sci.* 67, 1971–1986.
- Rose, S.J., et al., 2015. A new knock-in mouse model of L-DOPA-responsive dystonia. *Brain.* 138, 2987–3002.
- Saft, C., et al., 2018. Cannabinoids for treatment of dystonia in Huntington's disease. *J. Huntingtons Dis.* 7, 167–173.
- Sander, S.E., Richter, A., 2007. Effects of intrastriatal injections of glutamate receptor antagonists on the severity of paroxysmal dystonia in the dt(sz) mutant. *Eur. J. Pharmacol.* 563, 102–108.
- Scarduzio, M., et al., 2017. Strength of cholinergic tone dictates the polarity of dopamine D2 receptor modulation of striatal cholinergic interneuron excitability in DYT1 dystonia. *Exp. Neurol.* 295, 162–175.
- Schiffmann, S.N., et al., 1991. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. *J. Neurochem.* 57, 1062–1067.
- Schirinzi, T., et al., 2018. Dystonia as a network disorder: a concept in evolution. *Curr. Opin. Neurol.* 31, 498–503.
- Schmahmann, J.D., et al., 2019 Jul 8. The Theory and Neuroscience of Cerebellar Cognition. *Annu. Rev. Neurosci.* 42, 337–364.
- Schneider, S.A., et al., 2010. Modulatory effects of 5Hz rTMS over the primary somatosensory cortex in focal dystonia—an fMRI-TMS study. *Mov. Disord.* 25, 76–83.
- Schulte, G., Fredholm, B.B., 2003. Signalling from adenosine receptors to mitogen-activated protein kinases. *Cell. Signal.* 15, 813–827.
- Schwarz, C.S., Bressman, S.B., 2009. Genetics and treatment of dystonia. *Neurol. Clin.* 27, 697–718 vi.
- Sciamanna, G., et al., 2012. Cholinergic dysfunction alters synaptic integration between thalamostriatal and corticostriatal inputs in DYT1 dystonia. *J. Neurosci.* 32, 11991–12004.
- Sciamanna, G., et al., 2014. Negative allosteric modulation of mGlu5 receptor rescues striatal D2 dopamine receptor dysfunction in rodent models of DYT1 dystonia.

- Neuropharmacology. 85, 440–450.
- Shakkottai, V.G., et al., 2017. Current opinions and areas of consensus on the role of the cerebellum in dystonia. *Cerebellum*. 16, 577–594.
- Shimizu, T., et al., 2018. Stereotactic lesioning of the thalamic nucleus for the treatment of writer's cramp (focal hand dystonia). *Front. Neurol.* 9, 1008.
- Sibley, D.R., Monsma Jr., F.J., 1992. Molecular biology of dopamine receptors. *Trends Pharmacol. Sci.* 13, 61–69.
- Simonyan, K., 2018. Neuroimaging Applications in Dystonia. *Int. Rev. Neurobiol.* 143, 1–30.
- Simonyan, K., et al., 2013. Abnormal striatal dopaminergic neurotransmission during rest and task production in spasmodic dysphonia. *J. Neurosci.* 33, 14705–14714.
- Simonyan, K., et al., 2017. The direct basal ganglia pathway is hyperfunctional in focal dystonia. *Brain*. 140, 3179–3190.
- Siokas, V., et al., 2018. risk factor genes in patients with dystonia: a comprehensive review. *Tremor Other Hyperkinet. Mov. (N Y)*. 8, 559.
- Sjögren, B., 2017. The evolution of regulators of G protein signalling proteins as drug targets - 20 years in the making: IUPHAR review 21. *Br. J. Pharmacol.* 174, 427–437.
- Smeal, R.M., et al., 2008. Differences in excitatory transmission between thalamic and cortical afferents to single spiny efferent neurons of rat dorsal striatum. *Eur. J. Neurosci.* 28, 2041–2052.
- Stahl, S.M., Berger, P.A., 1981. Bromocriptine in dystonia. *Lancet*. 2, 745.
- Standaert, D.G., et al., 1994. Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. *J. Comp. Neurol.* 343, 1–16.
- Stern, T.A., Anderson, W.H., 1979. Benztropine prophylaxis of dystonic reactions. *Psychopharmacology* 61, 261–262.
- Sullivan, K.L., et al., 2005. Levetiracetam for the treatment of generalized dystonia. *Parkinsonism Relat. Disord.* 11, 469–471.
- Svedberg, M.M., et al., 2019 May 15. In vitro phosphodiesterase 10A (PDE10A) binding in whole hemisphere human brain using the PET radioligand [(18F)MNI-659. *Brain Res.* 1711, 140–145.
- Swash, M., et al., 1972. Treatment of involuntary movement disorders with tetra-benazine. *J. Neurol. Neurosurg. Psychiatry* 35, 186–191.
- Tanabe, L.M., et al., 2009. Primary dystonia: molecules and mechanisms. *Nat. Rev. Neurol.* 5, 598–609.
- Tanimura, A., et al., 2010. The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. *Neuron*. 65, 320–327.
- Tecuapetla, F., et al., 2016. Complementary contributions of striatal projection pathways to action initiation and execution. *Cell*. 166, 703–715.
- Tepper, J.M., et al., 2008. Feedforward and feedback inhibition in neostriatal GABAergic spiny neurons. *Brain Res. Rev.* 58, 272–281.
- Tepper, J.M., et al., 2010. Heterogeneity and diversity of striatal GABAergic interneurons. *Front. Neuroanat.* 4, 150.
- Tewari, A., et al., 2017. It's not just the basal ganglia: cerebellum as a target for dystonia therapeutics. *Mov. Disord.* 32, 1537–1545.
- Thengnatt, M.A., Jankovic, J., 2014. Treatment of dystonia. *Neurotherapeutics*. 11, 139–152.
- Thompson, V.B., et al., 2011. Convergent mechanisms in etiologically-diverse dystonias. *Expert Opin. Ther. Targets* 15, 1387–1403.
- Threlfell, S., Cragg, S.J., 2011. Dopamine signaling in dorsal versus ventral striatum: the dynamic role of cholinergic interneurons. *Front. Syst. Neurosci.* 5, 11.
- Threlfell, S., et al., 2010. Striatal muscarinic receptors promote activity dependence of dopamine transmission via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatum. *J. Neurosci.* 30, 3398–3408.
- Tiberi, M., et al., 1991. Cloning, molecular characterization, and chromosomal assignment of a gene encoding a second D1 dopamine receptor subtype: differential expression pattern in rat brain compared with the D1A receptor. *Proc. Natl. Acad. Sci. U. S. A.* 88, 7491–7495.
- Tison, F., et al., 2016. A phase 2a trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson's disease. *Mov. Disord.* 31, 1373–1380.
- Tolosa, E., Compta, Y., 2006. Dystonia in Parkinson's disease. *J. Neurol.* 253 (Suppl. 7), Vii7–13.
- Traynelis, S.F., et al., 2010. Glutamate receptor ion channels: structure, regulation, and function. *Pharmacol. Rev.* 62, 405–496.
- Traynor, J.R., et al., 2009. RGS9-2: probing an intracellular modulator of behavior as a drug target. *Trends Pharmacol. Sci.* 30, 105–111.
- Uchigashima, M., et al., 2007. Subcellular arrangement of molecules for 2-arachidonoylglycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. *J. Neurosci.* 27, 3663–3676.
- Uziel, A., et al., 2000. Distinct functions of the two isoforms of dopamine D2 receptors. *Nature*. 408, 199–203.
- Vander Heyden, A.B., et al., 2009. LULL1 retargets torsinA to the nuclear envelope revealing an activity that is impaired by the DYT1 dystonia mutation. *Mol. Biol. Cell* 20, 2661–2672.
- Vaughan, C.J., et al., 1997. Treatment of spastic dystonia with transdermal nicotine. *Lancet*. 350, 565.
- Wang, W.W., et al., 2017. a meta-analysis of adenosine A2A receptor antagonists on levodopa-induced dyskinesia In Vivo. *Front. Neurol.* 8, 702.
- Weiner, D.M., et al., 1990. Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. *Proc. Natl. Acad. Sci. U. S. A.* 87, 7050–7054.
- Wenzel, A., et al., 1996. Developmental and regional expression of NMDA receptor subtypes containing the NR2D subunit in rat brain. *J. Neurochem.* 66, 1240–1248.
- Wenzel, A., et al., 1997. NMDA receptor heterogeneity during postnatal development of the rat brain: differential expression of the NR2A, NR2B, and NR2C subunit proteins. *J. Neurochem.* 68, 469–478.
- Wichmann, T., 2008. Commentary: dopaminergic dysfunction in DYT1 dystonia. *Exp. Neurol.* 212, 242–246.
- Wood, M.R., et al., 2017. Discovery of VU0467485/AZ13713945: an M4 PAM evaluated as a preclinical candidate for the treatment of schizophrenia. *ACS Med. Chem. Lett.* 8, 233–238.
- Wu, Y.W., et al., 2015. Input- and cell-type-specific endocannabinoid-dependent LTD in the striatum. *Cell Rep.* 10, 75–87.
- Yardimci, N., et al., 2006. Levetiracetam in Meige's syndrome. *Acta Neurol. Scand.* 114, 63–66.
- Zadikoff, C., et al., 2011. Cannabinoid, CB1 agonists in cervical dystonia: failure in a phase IIa randomized controlled trial. *Basal Ganglia*. 1, 91–95.
- Zakirova, Z., et al., 2018. Mutations in THAP1/DYT6 reveal that diverse dystonia genes disrupt similar neuronal pathways and functions. *PLoS Genet.* 14, e1007169.
- Zhang, W., et al., 2002. Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice. *J. Neurosci.* 22, 6347–6352.
- Zhuang, X., et al., 2000. G(olf)alpha mediates dopamine D1 receptor signaling. *J. Neurosci.* 20, Rc91.
- Zimmerman, C.N., et al., 2017. Evaluation of AZD1446 as a Therapeutic in DYT1 Dystonia. *Front. Syst. Neurosci.* 11, 43.